ZOMETA® Reduces SREs From Bone Metastases In Lung Cancer Patients
Home


About ZOMETA
Breast Cancer
Lung Cancer
Prostate Cancer
Renal Cell Carcinoma
Multiple Myeloma

ZOMETA Patient Case Studies

Zometa Dosing & Administration

ZOMETA Safety & Tolerability

ZOMETA Clinical News

ZOMETA For Your Patients

Professional Resource Center

ZOMETA Around the World
Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
About ZOMETA: Lung Cancer About ZOMETA: defend against SREs across a broad range of tumor types
Threat of SREs What are SREs ZOMETA® reduces SREs dose ZOMETA® every 3 to 4 weeks References


ZOMETA® effectively helps to protect patients with lung cancer
from the threat of SREs


Time to first SRE,* ZOMETA vs placebo in patients with advanced lung cancer and other solid tumors6
*Excludes hypercalcemia of malignancy.


  • ZOMETA significantly delayed SREs vs placebo by more than 2 months (P=.023)6
  • ZOMETA reduced the risk of SREs vs placebo by 27% (P=NS)6

ZOMETA can delay and reduce SREs in patients with bone metastases from lung cancer and other solid tumors6